ArticleFrontiers in public health2025
The epidemiology and burden of atherosclerotic cardiovascular disease in China from 1990 to 2021: findings from the global burden of disease 2021.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- CD80 as an Important Immune Mediator and Therapeutic Target in Atherosclerosis.International journal of molecular sciences · 2026Review
- Burden of Systemic Inflammation Among Individuals with Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease in Northern China.Cardiology and therapy · 2026Article
- Phenotyping of mild behavioral impairment domains in multi-regional dementia-free older adults of Chinese ethnicity: impulse dyscontrol as the leading domain.The journal of prevention of Alzheimer's disease · 2026Article
- Article
- Association of Composite Metabolic Indices With Incident Carotid Plaque: A Chinese Cohort Study.Journal of the American Heart Association · 2026Article
- From Inflammation to Targeted Therapy: Leveraging Neutrophil, Platelet, RBC, and Macrophage Biology for Nanocarrier in Atherosclerosis.Current atherosclerosis reports · 2026Review
- Trends and disparities in obesity and atherosclerotic cardiovascular disease mortality in a 25-year retrospective analysis.Scientific reports · 2025Article
- Burden of lower-limb peripheral arterial disease in China and its comparison with global estimates, 1990-2021: analysis of global burden of disease (GBD) data by sex and age group.BMC cardiovascular disorders · 2025Article
- Vulnerable plaques in atherosclerosis: focus on angiogenesis-associated phenotypic crosstalk.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atherosclerotic cardiovascular disease (ASCVD) significantly threatens the health of the Chinese population. Understanding its epidemiological burden is vital for targeted interventions. Methods: Using Global Burden of Diseases (GBD) 2021 data, we assessed Disability-Adjusted Life Years (DALYs), incidence, prevalence, and mortality of ischemic heart disease (IHD), stroke, and lower extremity peripheral artery disease (PAD) in China in 2021. Joinpoint regression analyzed trends from 1990 to 2021, and risk factor contributions to the disease burden were evaluated. Findings: In 2021, age-standardized rates (ASRs) per 100,000 population for IHD (DALYs, incidence, prevalence, mortality) were 1856.5 (1548.7, 2159.8), 365.7 (293.3, 440.1), 3042.3 (2601.7, 3629.9), and 110.9 (92.4, 128.6), respectively, with males bearing a higher burden. For stroke, ASRs were 2648 (2253.4, 3076.9), 204.8 (181, 231.5), 1301.4 (1200.6, 1405.7), and 138 (116.7, 160.3), also higher in males. Lower extremity PAD showed ASRs of 8.4 (4.9, 14.3), 112.7 (97.8, 130.7), 1331.1 (1147.5, 1544.2), and 0.1 (0.1, 0.2), with a higher burden in females. Metabolic risks had the largest population-attributable fraction. Conclusion: As of 2021, the epidemiological burden of IHD, stroke, and PAD in China remains substantial, with notable gender disparities. Metabolic risks significantly contribute to this burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.